Key result
Moderate chronic kidney disease is associated with decreased fractional catabolic rates of VLDL and its subfractions compared with healthy controls.
Case-Control
Answers are grounded in this paper and cite their sources.
To determine the relative contribution of obesity and/or insulin resistance (IR) in the development of dyslipidemia in chronic kidney disease (CKD), we investigated the transport of apolipoprotein (apo) B-100 in nonobese, nondiabetic, nonnephrotic CKD subjects and healthy controls (HC). We determined total VLDL, VLDL1, VLDL2, intermediate density lipoprotein (IDL), and LDL-apoB-100 using intravenous D3-leucine, GC-MS, and multicompartmental modeling. Plasma apoC-III and apoB-48 were immunoassayed. In this case control study, we report higher plasma triglyceride, IDL-, VLDL-, VLDL1-, and VLDL2-apoB-100 concentrations in CKD compared with HC (P < 0.05). This was associated with decreased fractional catabolic rates [FCRs (pools/day)] [IDL:CKD 3.4 (1.6) vs. HC 5.0 (3.2), P < 0.0001; VLDL:CKD 4.8 (5.2) vs. HC 7.8 (4.8), P = 0.038; VLDL1:CKD 10.1 (8.5) vs. HC 29.5 (45.1), P = 0.007; VLDL2:CKD 5.4 (4.6) vs. HC 10.4 (3.4), P = 0.001] with no difference in production rates. Plasma apoC-III and apoB-48 were significantly higher in CKD (P < 0.001) and both correlated with impaired FCRs of VLDL, VLDL1, and VLDL2 apoB-100 (P < 0.05). In CKD, apoC-III concentration was the only independent predictor of clearance defects in VLDL and its subfractions. Moderate CKD in the absence of central adiposity and IR is associated with mild hypertriglyceridemia due to delayed catabolism of triglyceride rich lipoproteins, IDL, and VLDL, without changes in production rate. Altered apoC-III metabolism may contribute to dyslipidemia in CKD, and this requires further investigation. To determine the relative contribution of obesity and/or insulin resistance (IR) in the development of dyslipidemia in chronic kidney disease (CKD), we investigated the transport of apolipoprotein (apo) B-100 in nonobese, nondiabetic, nonnephrotic CKD subjects and healthy controls (HC). We determined total VLDL, VLDL1, VLDL2, intermediate density lipoprotein (IDL), and LDL-apoB-100 using intravenous D3-leucine, GC-MS, and multicompartmental modeling. Plasma apoC-III and apoB-48 were immunoassayed. In this case control study, we report higher plasma triglyceride, IDL-, VLDL-, VLDL1-, and VLDL2-apoB-100 concentrations in CKD compared with HC (P < 0.05). This was associated with decreased fractional catabolic rates [FCRs (pools/day)] [IDL:CKD 3.4 (1.6) vs. HC 5.0 (3.2), P < 0.0001; VLDL:CKD 4.8 (5.2) vs. HC 7.8 (4.8), P = 0.038; VLDL1:CKD 10.1 (8.5) vs. HC 29.5 (45.1), P = 0.007; VLDL2:CKD 5.4 (4.6) vs. HC 10.4 (3.4), P = 0.001] with no difference in production rates. Plasma apoC-III and apoB-48 were significantly higher in CKD (P < 0.001) and both correlated with impaired FCRs of VLDL, VLDL1, and VLDL2 apoB-100 (P < 0.05). In CKD, apoC-III concentration was the only independent predictor of clearance defects in VLDL and its subfractions. Moderate CKD in the absence of central adiposity and IR is associated with mild hypertriglyceridemia due to delayed catabolism of triglyceride rich lipoproteins, IDL, and VLDL, without changes in production rate. Altered apoC-III metabolism may contribute to dyslipidemia in CKD, and this requires further investigation. Cardiovascular (CV) morbidity and mortality is increased in patients with mild renal dysfunction (1Go A.S. Chertow G.M. Fan D. McCulloch C.E. Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N. Engl. J. Med. 2004; 351: 1296-1305Crossref PubMed Scopus (9157) Google Scholar). While the precise mechanisms for this increase in CV event are unknown, both traditional and novel CV risk factors common to both disease processes have been implicated. Renal dyslipidemia is characterized by raised triglyceride, low HDL, and normal total cholesterol concentration. However, dysregulation of lipoprotein metabolism can develop early in renal disease with alteration in apolipoprotein concentrations in spite of normal plasma lipid levels (2Samuelsson O. Attman P.O. Knight-Gibson C. Kron B. Larsson R. Mulec H. Weiss L. Alaupovic P. Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency.Nephrol. Dial. Transplant. 1994; 9: 1580-1585PubMed Google Scholar). Raised plasma triglyceride concentration is now recognized as an independent risk factor for cardiovascular disease (CVD) in nonrenal subjects (3Sarwar N. Danesh J. Eiriksdottir G. Sigurdsson G. Wareham N. Bingham S. Boekholdt S.M. Khaw K.T. Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.Circulation. 2007; 115: 450-458Crossref PubMed Scopus (1125) Google Scholar) and may reflect the direct atherogenic potential of triglyceride-rich lipoproteins (TRLs), particularly VLDLs and intermediate density lipoproteins (IDLs) (4Ginsberg H.N. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism.Circulation. 2002; 106: 2137-2142Crossref PubMed Scopus (216) Google Scholar). VLDL and IDL apolipoprotein (apo) B-100 accumulation has been reported in kinetic turnover studies of dialysis patients (5Chan P.C. Persaud J. Varghese Z. Kingstone D. Baillod R.A. Moorhead J.F. Apolipoprotein B turnover in dialysis patients: its relationship to pathogenesis of hyperlipidemia.Clin. Nephrol. 1989; 31: 88-95PubMed Google Scholar, 6Ikewaki K. Schaefer J.R. Frischmann M.E. Okubo K. Hosoya T. Mochizuki S. Dieplinger B. Trenkwalder E. Schweer H. Kronenberg F. et al.Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2615-2622Crossref PubMed Scopus (61) Google Scholar, 7Prinsen B.H.C.M. Rabelink T.J. Romijn J.A. Bisschop P.H. De Barse M.M.J. De Boer J. van Haeften T.W. Barrett P.H.R. Berger R. de Sain-van der Velden M. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis.Kidney Int. 2004; 65: 1064-1075Abstract Full Text Full Text PDF PubMed Scopus (36) Google Scholar) and in obese chronic kidney disease (CKD) patients not yet on dialysis (8Batista M.C. Welty F.K. Diffenderfer M.R. Sarnak M.J. Schaefer E.J. Lamon-Fava S. Asztalos B.F. Dolnikowski G.G. Brousseau M.E. Marsh J.B. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.Metabolism. 2004; 53: 1255-1261Abstract Full Text Full Text PDF PubMed Scopus (65) Google Scholar). However, the mechanism for altered apoB-100 metabolism in CKD remains uncertain with inconsistent reports of either delayed catabolism alone (7Prinsen B.H.C.M. Rabelink T.J. Romijn J.A. Bisschop P.H. De Barse M.M.J. De Boer J. van Haeften T.W. Barrett P.H.R. Berger R. de Sain-van der Velden M. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis.Kidney Int. 2004; 65: 1064-1075Abstract Full Text Full Text PDF PubMed Scopus (36) Google Scholar) or combination of reduced clearance and overproduction of VLDL apoB-100 particles (8Batista M.C. Welty F.K. Diffenderfer M.R. Sarnak M.J. Schaefer E.J. Lamon-Fava S. Asztalos B.F. Dolnikowski G.G. Brousseau M.E. Marsh J.B. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.Metabolism. 2004; 53: 1255-1261Abstract Full Text Full Text PDF PubMed Scopus (65) Google Scholar). Dyslipidemia of CKD is phenotypically similar to that seen in the metabolic syndrome and obesity. resistance is in early CKD J. P. V. V. J. resistance and risk of chronic kidney disease in Nephrol. PubMed Scopus Google Scholar, S. K. H. T. T. resistance in patients with chronic kidney J. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar) and central may contribute to the dyslipidemia in in hemodialysis P. D. B. J. role of adiposity and insulin resistance in dyslipidemia of chronic renal J. Full Text PDF PubMed Scopus Google Scholar) and nonrenal subjects S.M. resistance and adiposity lipoprotein and the 2005; Full Text Full Text PDF PubMed Scopus Google Scholar) have role for IR and adiposity in the development of abnormal lipoproteins kinetic studies have that IR the of triglyceride-rich particles without in the VLDL2 M. J. M.J. P. J. B. C. M.R. of by is of Thromb. Vasc. Biol. 2005; 25: PubMed Scopus Google Scholar, D. J. M.J. production of not VLDL2 is to insulin resistance in 2004; Full Text Full Text PDF PubMed Scopus Google Scholar). of as plasma and of may contribute to the development of dyslipidemia in increased plasma apoC-III of CKD Dyslipidemia of chronic renal the and potential J. Renal PubMed Scopus Google Scholar) the catabolism of by the of and H.N. P. R. Apolipoprotein B metabolism in subjects with of and that apolipoprotein catabolism of triglyceride-rich lipoproteins by lipoprotein in PubMed Scopus Google Scholar) and with to clearance R. E. T. S. of and of on the metabolism of and PubMed Scopus Google Scholar). is common in CKD and has been associated with the development of an abnormal lipid Cardiovascular disease, and the with and in patients with chronic renal Full Text Full Text PDF PubMed Scopus Google Scholar). apoC-III T. is by B 1994; PubMed Scopus Google Scholar) and may with lipoprotein in reduced clearance Z. O. S. J. E.J. J.A. and Med. 2007; PubMed Scopus Google Scholar). of VLDL and IDL-, and LDL-apoB-100 in CKD subjects for the of IR has not been We that patients with moderate CKD clearance defects in total VLDL, VLDL1, and VLDL2 and IDL apoB-100 with We to the transport of VLDL and IDL, and apoB-100 in nondiabetic, nonnephrotic CKD subjects without central adiposity and/or We the plasma plasma and lipoprotein CKD by of in Renal subjects and healthy controls were the and of Western controls were to the CKD subjects on and VLDL, IDL, and IDL kinetic of the control subjects were studies in Barrett P.H. Apolipoprotein B-100 in with plasma apolipoprotein 2002; Full Text PDF PubMed Scopus Google studies not kinetic on and VLDL2 We control subjects in we total VLDL and VLDL of healthy controls on and to CKD in we and VLDL2 kinetic subjects were and and not have central adiposity of in and in as by the S. S. cholesterol and J. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). and control subjects no or of renal disease or chronic that the of CKD subjects were syndrome CV disease, abnormal and of and of the apolipoprotein was not in the control of of dyslipidemia were in the CKD of premature in CKD subjects on lipid not have CV or disease, to the of the CKD subjects were on CKD subjects were of renal disease kidney disease, and In CKD the cause of renal dysfunction was study was by the and was in with the by the of in was This is with the New subjects to the metabolic in the of the kinetic study and were and was using was using and using A was an and were for of and only for the of the were and and and and the were in the and were for to plasma and VLDL, VLDL1, VLDL2, IDL, and concentrations were using of the as by et L. N. P. P. B. G. of apolipoprotein B concentration in plasma lipoproteins by and Full Text Full Text PDF PubMed Google Scholar) In total VLDL, IDL, and were of plasma by and VLDL2 were total VLDL in of F. T. and of and New Scholar). was and by with for and and to an Barrett P.H.R. D. of for and for kinetic studies of 2002; Full Text Full Text PDF PubMed Google Scholar). in plasma was by of with was determined using with of and were of were in Plasma cholesterol and triglyceride concentrations were determined by was by an using was by total was by the Plasma total and concentrations were determined by Plasma and were by the Plasma apoB-48 concentration was in plasma by using apoB-48 of S. of B-48 and of B-48 in by PubMed Scopus Google Scholar). was in plasma using of Plasma was determined using an of and Plasma insulin was by and by resistance was by the insulin was using and were using and was and were determined using the on an was for the and of the for the VLDL-, IDL-, and were Barrett P.H. Apolipoprotein B-100 in with plasma apolipoprotein 2002; Full Text PDF PubMed Scopus Google Scholar). In of the of that plasma This is to an that for the for the and of apoB-100 are to the of apoB-100 in VLDL, the and VLDL apoB-100 of plasma IDL was by and the of IDL to or its of IDL is by and an fractional catabolic rates of VLDL, IDL, and were the the production rates were as the of FCRs and the plasma concentration by plasma Plasma was as of was for the This of C. K. Barrett P.H.R. N. Mochizuki S. et of the low-density lipoprotein is associated with increased apolipoprotein B-100 Thromb. Vasc. Biol. 2005; 25: PubMed Scopus Google that plasma This is to an that for the and of apoB-100 and the of apoB-100 in the VLDL1, to and apoB-100 of apoB-100 in VLDL2 are by and the and VLDL2 apoB-100 IDL apoB-100 is by and IDL apoB-100 is either plasma or to LDL-apoB-100 is this or with an VLDL1, VLDL2, IDL, and apoB-100 FCRs were the the production rates were as the of and as were using are as and to for the of the the were using the were using and was as P < and of the CKD subjects and healthy controls are in were for and plasma and not significantly was no difference in of and P 0.05). the CKD not have the and were for the and the of and were not total (8Batista M.C. Welty F.K. Diffenderfer M.R. Sarnak M.J. Schaefer E.J. Lamon-Fava S. Asztalos B.F. Dolnikowski G.G. Brousseau M.E. Marsh J.B. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.Metabolism. 2004; 53: 1255-1261Abstract Full Text Full Text PDF PubMed Scopus (65) Google M. J. M.J. P. J. B. C. M.R. of by is of Thromb. Vasc. Biol. 2005; 25: PubMed Scopus Google S. K. H. T. T. resistance in patients with chronic kidney J. 2005; Full Text Full Text PDF PubMed Scopus Google P. D. B. J. role of adiposity and insulin resistance in dyslipidemia of chronic renal J. Full Text PDF PubMed Scopus Google vs. total P. D. B. J. role of adiposity and insulin resistance in dyslipidemia of chronic renal J. Full Text PDF PubMed Scopus Google (7Prinsen B.H.C.M. Rabelink T.J. Romijn J.A. Bisschop P.H. De Barse M.M.J. De Boer J. van Haeften T.W. Barrett P.H.R. Berger R. de Sain-van der Velden M. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis.Kidney Int. 2004; 65: 1064-1075Abstract Full Text Full Text PDF PubMed Scopus (36) Google S.M. resistance and adiposity lipoprotein and the 2005; Full Text Full Text PDF PubMed Scopus Google and (4Ginsberg H.N. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism.Circulation. 2002; 106: 2137-2142Crossref PubMed Scopus (216) Google P and of CKD and control = = Barrett P.H. Apolipoprotein B-100 in with plasma apolipoprotein 2002; Full Text PDF PubMed Scopus Google S. K. H. T. T. resistance in patients with chronic kidney J. 2005; Full Text Full Text PDF PubMed Scopus Google S. K. H. T. T. resistance in patients with chronic kidney J. 2005; Full Text Full Text PDF PubMed Scopus Google T. is by B 1994; PubMed Scopus Google (3Sarwar N. Danesh J. Eiriksdottir G. Sigurdsson G. Wareham N. Bingham S. Boekholdt S.M. Khaw K.T. Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.Circulation. 2007; 115: 450-458Crossref PubMed Scopus (1125) Google P. D. B. J. role of adiposity and insulin resistance in dyslipidemia of chronic renal J. Full Text PDF PubMed Scopus Google F. T. and of and New R. E. T. S. of and of on the metabolism of and PubMed Scopus Google L. N. P. P. B. G. of apolipoprotein B concentration in plasma lipoproteins by and Full Text Full Text PDF PubMed Google are as To in to by in to by insulin in to by in are as To in to by in to by insulin in to by the CKD significantly higher and (P < 0.001) CKD subjects significantly higher triglyceride, and apoB-48 concentrations compared with healthy controls (P < 0.05). plasma concentration was not the of was significantly reduced in the CKD subjects (P < 0.05). and were not significantly CKD and healthy control subjects and apolipoprotein concentrations in CKD and control = = cholesterol cholesterol J.A. resistance and triglyceride levels in renal 2005; Full Text Full Text PDF PubMed Scopus Google cholesterol R. S. L. R. N. M. et of the apolipoprotein in 2005; 31: PubMed Scopus Google R. S. L. R. N. M. et of the apolipoprotein in 2005; 31: PubMed Scopus Google T. T. T. S. M. increase of apolipoprotein in patients with renal Full Text Full Text PDF Scopus Google Knight-Gibson C. O. Attman P.O. Alaupovic P. Lipoprotein abnormalities and the impaired in renal Int. 2002; Full Text Full Text PDF PubMed Scopus Google (7Prinsen B.H.C.M. Rabelink T.J. Romijn J.A. Bisschop P.H. De Barse M.M.J. De Boer J. van Haeften T.W. Barrett P.H.R. Berger R. de Sain-van der Velden M. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis.Kidney Int. 2004; 65: 1064-1075Abstract Full Text Full Text PDF PubMed Scopus (36) Google S. K. H. T. T. resistance in patients with chronic kidney J. 2005; Full Text Full Text PDF PubMed Scopus Google P. in renal disease: and Dial. 2002; PubMed Scopus Google are as To and in to by in to by apoC-III in to by in are as To and in to by in to by apoC-III in to by plasma VLDL-, IDL-, and LDL-apoB-100 concentrations and kinetic in the CKD subjects and healthy controls in the plasma and VLDL2 apoB-100 concentrations and kinetic in of CKD subjects and healthy controls of levels were significantly the of CKD = and healthy control = subjects with VLDL vs. HC R. S. L. R. N. M. et of the apolipoprotein in 2005; 31: PubMed Scopus Google P = with CKD subjects significantly higher total IDL, VLDL, VLDL1, and VLDL2 apoB-100 kinetic changes were to FCRs (P < without in production rates. concentration and were not significantly were no in the of rates of VLDL to IDL IDL to to IDL to VLDL2 and VLDL2 to IDL of total VLDL, IDL, and apoB-100 in the CKD and control = = concentrations VLDL IDL VLDL IDL VLDL IDL VLDL to IDL IDL to as in of and VLDL2 apoB-100 in the CKD and control subjects as = = concentrations R. S. L. R. N. M. et of the apolipoprotein in 2005; 31: PubMed Scopus Google VLDL2 IDL VLDL2 IDL VLDL2 IDL IDL to to IDL to VLDL2 VLDL2 to IDL apoB100 are as as in as are as as To the of kinetic and VLDL2 apoB-100 in CKD with apoC-III and control with low This the and the and VLDL2 apoB-100 of for of and VLDL2 FCRs in the CKD and control subjects are as VLDL1, apoB-100 VLDL2 apoB-100 apoB-100 VLDL2 apoB-100 was and triglyceride concentrations in the CKD subjects = P = and in the CKD subjects with total VLDL apoB-100 = P = = P = this not for the FCRs of apoB-100 = P = = P = and VLDL2 apoB-100 = P = = P = Plasma apoC-III and apoB-48 concentrations were significantly and correlated with the total VLDL apoB-100 = P = 0.007; = P = of apoB-100 = P = = P = and of VLDL2 apoB-100 = P = = P = in the CKD was plasma apoC-III and plasma apoB-48 concentration = P = in the CKD In that apoB-48 and apoC-III was the only independent predictor of the FCRs of total VLDL = P = = P = and VLDL2 = P = was only correlated with total VLDL apoB-100 = P = not with apoB-100 = P = VLDL2 apoB-100 = P = We have that subjects with moderate CKD have mild hypertriglyceridemia that to higher plasma concentrations of total VLDL, VLDL1, VLDL2, and IDL This of impaired clearance of IDL and of total VLDL its with no difference in production rates. We that plasma apoC-III levels in CKD clearance defects in total VLDL, VLDL1, and VLDL2 apoB-100 kinetic are on multicompartmental of VLDL and apoB-100 that with studies Barrett P.H.R. of and on apolipoprotein B-100 in obese subjects with 2002; PubMed Scopus Google Scholar, T. D. M.J. G. J. D. Apolipoprotein B metabolism and the of VLDL and Full Text Full Text PDF PubMed Google Scholar). IR to changes in lipoprotein metabolism and development of dyslipidemia in subjects with and the metabolic A kinetic study by et (8Batista M.C. Welty F.K. Diffenderfer M.R. Sarnak M.J. Schaefer E.J. Lamon-Fava S. Asztalos B.F. Dolnikowski G.G. Brousseau M.E. Marsh J.B. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.Metabolism. 2004; 53: 1255-1261Abstract Full Text Full Text PDF PubMed Scopus (65) Google Scholar) in obese CKD subjects reported higher VLDL and IDL apoB-100 to in clearance not in production rate. of the metabolic syndrome and obesity have to dyslipidemia in that study, was by of CKD the relative of adiposity or IR not studies by et (5Chan P.C. Persaud J. Varghese Z. Kingstone D. Baillod R.A. Moorhead J.F. Apolipoprotein B turnover in dialysis patients: its relationship to pathogenesis of hyperlipidemia.Clin. Nephrol. 1989; 31: 88-95PubMed Google Scholar) in dialysis patients reported increase in VLDL apoB-100 concentration due to decreased VLDL fractional catabolic and increased production rate. A study in hemodialysis patients reported impaired catabolism of IDL delayed clearance and decreased production of and no difference in the metabolism of VLDL K. Schaefer J.R. Frischmann M.E. Okubo K. Hosoya T. Mochizuki S. Dieplinger B. Trenkwalder E. Schweer H. Kronenberg F. et al.Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2615-2622Crossref PubMed Scopus (61) Google Scholar). In study of peritoneal dialysis et (7Prinsen B.H.C.M. Rabelink T.J. Romijn J.A. Bisschop P.H. De Barse M.M.J. De Boer J. van Haeften T.W. Barrett P.H.R. Berger R. de Sain-van der Velden M. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis.Kidney Int. 2004; 65: 1064-1075Abstract Full Text Full Text PDF PubMed Scopus (36) Google Scholar) reported increased apoB-100 due to increased and decreased increased VLDL2 apoB-100 was only of delayed increase in apoB-100 was by IR and increased kinetic in of nonobese, CKD subjects using We clearance defects in total VLDL, VLDL1, and VLDL2 apoB-100 without changes in production that VLDL and apoB-100 overproduction in CKD subjects is by adiposity and the of IR may further the lipid abnormalities associated with of and/or triglyceride-rich lipoproteins in CKD has been to Knight-Gibson C. O. Attman P.O. Alaupovic P. Lipoprotein abnormalities and the impaired in renal Int. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar). total plasma apoC-III concentration and accumulation of apoC-III in VLDL particles can in early CKD E. J. and lipoproteins and concentration in patients with chronic renal 2002; PubMed Scopus Google Scholar). changes in lipoproteins may for and in reduced M. H. J. P. that reduced lipoprotein is not factor for hypertriglyceridemia in renal Int. Full Text PDF PubMed Scopus Google Scholar). In this study, we that higher apoC-III concentration was associated with VLDL, VLDL1, and VLDL2 apoB-100 This that delayed catabolism of in increased plasma apoC-III concentration or that apoC-III to reduced clearance of are potential mechanisms for the increase apoC-III in Renal is associated with of may triglyceride-rich particles for G. J. P. abnormal triglyceride-rich lipoprotein apolipoprotein PubMed Scopus Google Scholar). kidney is in apoC-III plasma G. J. P. abnormal triglyceride-rich lipoprotein apolipoprotein PubMed Scopus Google apoC-III to early In CKD, is of P. in renal disease: and Dial. 2002; PubMed Scopus Google have been to increase the of apoC-III R. S. L. R. N. M. et of the apolipoprotein in 2005; 31: PubMed Scopus Google Scholar). However, of were not in CKD subjects early disease and were not insulin is an mechanism for the raised plasma apoC-III and delayed catabolism of VLDL apoB-100 and its in subjects with early We not in that for the VLDL apoB-100 catabolism in the CKD While the of may is correlated with = P < 0.001) P. G. F. T. Lipoprotein and in plasma and increase are with to plasma Thromb. Vasc. Biol. PubMed Scopus Google Scholar). that in early CKD subjects without in is an factor to catabolism of of and in Int. Google Scholar) and accumulation of T. S. K. Int. Google Scholar) in the of CKD can to alteration in and to of in the of This may of VLDL apoB-100 and and of in plasma may changes in in vivo in of lipoprotein metabolism with accumulation of lipoproteins is to in obesity, and K. lipoprotein overproduction in PubMed Scopus Google Scholar, T. T. T. S. M. increase of apolipoprotein in patients with renal Full Text Full Text PDF Scopus Google Scholar). raised plasma apoB-48 concentration has been reported in renal disease in patients T. T. T. S. M. increase of apolipoprotein in patients with renal Full Text Full Text PDF Scopus Google we report for the that plasma apoB-48 concentration is in subjects and that this is associated with VLDL apoB-100 This that early CKD the metabolism of lipoproteins, may with lipoproteins for common clearance Barrett P.H. Apolipoprotein B-100 in with plasma apolipoprotein 2002; Full Text PDF PubMed Scopus Google Scholar, D. for triglyceride mechanism for and low density lipoproteins in PubMed Scopus Google Scholar). concentration is in IDL and and is of in the studies lipoprotein metabolism in early study has have an of the particularly with the and VLDL2 is the potential for that control subjects were for normal lipid were no lipid for in the CKD However, the cases were not for dyslipidemia and for dyslipidemia CKD were potential is the in apoB-100 VLDL However, has been reported that in the apoB-48 to only of total plasma VLDL H. C. and of apolipoprotein B-48 in VLDL, IDL, and 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). In study, the contribution of apoB-48 to total VLDL was is with reports H. C. and of apolipoprotein B-48 in VLDL, IDL, and 2005; Full Text Full Text PDF PubMed Scopus Google Scholar). studies of apoB-48 in lipoprotein in the of of VLDL triglyceride was not and further to increase of lipoprotein metabolism in A of study, is the of obese subjects with and This with an to the contribution of CKD alone to the dysregulation of lipoprotein We that moderate CKD in the absence of central may to mild hypertriglyceridemia with accumulation of particularly VLDL and IDL, and that this is to In CKD, this relationship may to abnormal metabolism of apoC-III or apoC-III and apoB-48 in the CKD subjects that apoC-III may contribute to hypertriglyceridemia and accumulation of J.A. resistance and triglyceride levels in renal 2005; Full Text Full Text PDF PubMed Scopus Google Scholar, M. T. M. S. M. G. in in dialysis Int. Full Text PDF PubMed Scopus Google Scholar). This further investigation. To the relationship apoC-III and VLDL vivo studies the of VLDL CKD to as for plasma triglyceride is recognized as an risk factor for in the Plasma triglyceride is risk factor for cardiovascular disease independent of lipoprotein cholesterol of prospective PubMed Google Scholar) and may an in CKD subjects have the VLDL1, of plasma triglyceride, the of atherogenic particles and may contribute to the accumulation of particles and to changes in T. D. M.J. G. J. D. Apolipoprotein B metabolism and the of VLDL and Full Text Full Text PDF PubMed Google Scholar, M.R. to PubMed Scopus Google Scholar). of VLDL catabolism may for CV risk in early J. and for and for We for apolipoprotein chronic kidney disease cardiovascular cardiovascular disease fractional catabolic intermediate density lipoprotein insulin resistance triglyceride-rich lipoprotein
No takes yet. Share an insight, caveat, or question.
Chan et al. (2009) conducted a case-control in Chronic Kidney Disease. Chronic kidney disease vs. Healthy controls was evaluated on Fractional catabolic rate of VLDL apoB-100 (pools/day) (p=0.038). Moderate chronic kidney disease is associated with decreased fractional catabolic rates of VLDL and its subfractions compared with healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: